Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay
Open Access
- 12 January 2015
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 11 (2) , 164-171
Abstract
ABHD16A is identified as a major enzyme catalyzing production of lyso-PS from phosphatidylserine (PS). A new ABHD16A inhibitor and knockout mice show a dynamic interplay occurring during inflammation between ABHD16A and disease-linked ABHD12, an enzyme that degrades lyso-PS. ABHD16A is identified as a major enzyme catalyzing production of lyso-PS from phosphatidylserine (PS). A new ABHD16A inhibitor and knockout mice show a dynamic interplay occurring during inflammation between ABHD16A and disease-linked ABHD12, an enzyme that degrades lyso-PS. Lysophosphatidylserines (lyso-PSs) are a class of signaling lipids that regulate immunological and neurological processes. The metabolism of lyso-PSs remains poorly understood in vivo. Recently, we determined that ABHD12 is a major brain lyso-PS lipase, implicating lyso-PSs in the neurological disease polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC), which is caused by null mutations in the ABHD12 gene. Here, we couple activity-based profiling with pharmacological and genetic methods to annotate the poorly characterized enzyme ABHD16A as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems. We describe a small-molecule inhibitor of ABHD16A that depletes lyso-PSs from cells, including lymphoblasts derived from subjects with PHARC. In mouse macrophages, disruption of ABHD12 and ABHD16A respectively increases and decreases both lyso-PSs and lipopolysaccharide-induced cytokine production. Finally, Abhd16a−/− mice have decreased brain lyso-PSs, which runs counter to the elevation in lyso-PS in Abhd12−/− mice. Our findings illuminate an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo, designating these enzymes as potential targets for treating neuroimmunological disorders.Keywords
This publication has 50 references indexed in Scilit:
- An X chromosome-wide association analysis identifies variants inGPR174as a risk factor for Graves’ diseaseJournal of Medical Genetics, 2013
- DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responsesNature Chemical Biology, 2012
- Click-generated triazole ureas as ultrapotent in vivo–active serine hydrolase inhibitorsNature Chemical Biology, 2011
- Quantitative reactivity profiling predicts functional cysteines in proteomesNature, 2010
- Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid MetabolismThe American Journal of Human Genetics, 2010
- A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelBritish Journal of Pharmacology, 2010
- Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case StudyJournal of Biological Chemistry, 2010
- Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profilingBioorganic & Medicinal Chemistry Letters, 2008
- Sphingosine 1-phosphate chemical biologyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-ArachidonoylglycerolChemistry & Biology, 2007